Regeneron, Inovio agree to study glioblastoma combination therapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Regeneron Pharmaceuticals Inc. and Inovio Pharmaceuticals Inc. announced a clinical study agreement for a Phase Ib/IIa immuno-oncology trial.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.